Route of Estrogen Administration Helps to Determine Growth Hormone (GH) Replacement Dose in GH-Deficient Adults1
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
We prospectively studied two groups of GH-deficient patients during GH therapy based upon exposure of the liver to elevated (oral estrogen) or not elevated (endogenous or transdermal) sources of estrogen. We wondered whether higher concentrations of estrogen at the liver level (oral estrogen) might inhibit insulin-like growth factor I (IGF-I) secretion and alter exogenous GH requirements. In this study we compared GH replacement requirements in these two groups of women as well as with GH-treated adult hypopituitary males. The final GH dose was based upon maintenance IGF-I levels in the mid- to high normal range adjusted for age and sex or symptom tolerance. Each group [women taking oral estrogen (n = 12), women not taking oral estrogen (n = 13), and men (n = 12)] was similar in age and final IGF-I concentration. Women taking oral estrogen required 10.6 +/- 0.7 microg/kg x day or 867 +/- 45 microg/day GH, women not taking oral estrogen required 5.0 +/- 0.7 microg/kg x day or 424 +/- 57 microg/day, and men required 4.1 +/- 0.6 microg/kg x day or 376 +/- 49 microg/day to achieve similar IGF-I concentrations. GH requirements in men were not different from those in women not taking oral estrogen, but the GH requirements in both groups were significantly different from GH requirements in women taking oral estrogen. These observations may be useful in anticipating appropriate starting and final doses of GH in adult hypopituitary patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IRANMANESH, A., LIZARRALDE, G., & VELDHUIS, J. D. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1081 · Cited by 672
WEISSBERGER, A. J., HO, K. K. Y., & LAZARUS, L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-2-374 · Cited by 514
van den Berg, G., Veldhuis, J. D., Frölich, M., & Roelfsema, F. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.7.8675561 · Cited by 293
Gender differences in secretory activity of the human somatotropic (growth hormone) axis
Veldhuis, J. D. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1340287 · Cited by 102
Which adults develop side-effects of growth hormone replacement?
Holmes, S. J., & Shalet, S. M. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb01908.x · Cited by 101 · cited 1×
“More recent reports ( 12 , 13) have suggested that adults are more prone to side-effects from GH therapy than children, and that symptom tolerance is often a limiting factor in adult GH replacement therapy.”
Background
Cited by
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Estrogen Regulation of Growth Hormone Action
Leung, K.-C., Johannsson, G., Leong, G. M., & Ho, K. K. Y. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0035 · Cited by 542
Serum levels of insulin-like growth factor I and its binding proteins in health and disease
Juul, A. (2003) · Growth Hormone & IGF Research · doi:10.1016/s1096-6374(03)00038-8 · Cited by 467
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., Shalet, S. M., Vance, M. L., & for The Endocrine Society’s Clinical Guidelines Subcommittee (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2227 · Cited by 424
Yuen, K. C. J., Biller, B. M. K., Radovick, S., Carmichael, J. D., Jasim, S., Pantalone, K. M., & Hoffman, A. R. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0405 · Cited by 298
Rich-Edwards, J. W., Kaiser, U. B., Chen, G. L., Manson, J. E., & Goldstein, J. M. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00246 · Cited by 273
Hoffman, A. R., Kuntze, J. E., Baptista, J., Baum, H. B. A., Baumann, G. P., Biller, B. M. K., Clark, R. V., Cook, D., Inzucchi, S. E., Kleinberg, D., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030346 · Cited by 185
Self-citationOptimizing GH Therapy in Adults and Children
Drake, W. M., Howell, S. J., Monson, J. P., & Shalet, S. M. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.4.0438 · Cited by 185
Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women
Wolthers, T., Hoffman, D. M., Nugent, A. G., Duncan, M. W., Umpleby, M., & Ho, K. K. Y. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1191 · Cited by 114
Torres-Santiago, L., Mericq, V., Taboada, M., Unanue, N., Klein, K. O., Singh, R., Hossain, J., Santen, R. J., Ross, J. L., & Mauras, N. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4243 · Cited by 99
“These results are similar to previous studies using oral and TD estrogen preparations (1, 3, 23) and the hepatic firstpass effect of oral estrogen has been postulated as a principal mechanism possibly due to up-regulation of suppressors of cytokine signaling (SOCS)-2 and -3, which inhibit GH signaling (24).”
ResultTaboada, M., Santen, R., Lima, J., Hossain, J., Singh, R., Klein, K. O., & Mauras, N. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1449 · Cited by 82
“IGF-I levels decreased after oral CEE but remained constant during E2 TD in postmenopausal women (6, 7), and postmenopausal hypopituitary women needed more GH to normalize IGF-I when taking CEE orally than E2 TD (8).”
BackgroundMauras, N., Shulman, D., Hsiang, H. Y., Balagopal, P., & Welch, S. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0671 · Cited by 65
“(30) also reported that when using oral estrogen, the dose of GH used in GHdeficient states needs to be increased.”
BackgroundMo, D., Fleseriu, M., Qi, R., Jia, N., Child, C. J., Bouillon, R., & Hardin, D. S. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00098-4 · Cited by 64
Estrogen replacement in women of fertile years with hypopituitarism
Mah, P. M., Webster, J., Jönsson, P., Feldt-Rasmussen, U., Koltowska-Häggström, M., & Ross, R. J. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1207 · Cited by 57
Filipsson, H., & Johannsson, G. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0319 · Cited by 50
The impact of dose and route of estrogen administration on the somatotropic axis in normal women.
Lissett, C. A., & Shalet, S. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-022036 · Cited by 48
Gibney, J., Johannsson, G., Leung, K.-C., & Ho, K. K. Y. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0173 · Cited by 40
Diagnosis of GH Deficiency in Adults--How Good Do the Criteria Need to Be?
Molitch, M. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8339 · Cited by 27
Rota, F., Savanelli, M. C., Tauchmanova, L., Savastano, S., Lombardi, G., Colao, A., & Di Somma, C. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03345574 · Cited by 25
Attallah, H., Friedlander, A. L., Nino-Murcia, M., & Hoffman, A. R. (2007) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0020021 · Cited by 19
Metadata
- Authors
- Cook, D. M., Ludlam, W. H., & Cook, M. B.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1999-11
- Volume
- 84
- Issue
- 11
- Pages
- 3956-3960
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2026803114
- Cited by
- 129
- References
- 5
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.